Corneal endothelial disease
Kowa Research Institute Inc. is involved in clinical research for Fuchs endothelial corneal dystrophy, with a focus on preserving and improving visual acuity after corneal procedures. Its studies center on treatment approaches used around descemetorhexis and cataract-related surgery in patients with endothelial dysfunction.
- Fuchs endothelial corneal dystrophy
- Best corrected visual acuity (BCVA)
- Descemetorhexis
- Cataract surgery
The sponsor’s ophthalmic research includes interest in post-procedural recovery and corneal clarity in a setting of progressive endothelial cell loss.
Ophthalmic therapeutics
Within eye disease research, the sponsor evaluates Ripasudil (K-321) for its role in supporting corneal function and improving patient outcomes in Fuchs dystrophy. The therapeutic emphasis is on interventions used after corneal tissue removal procedures and their effect on functional vision.
- Ripasudil (K-321)
- Corneal function
- Post-surgical vision recovery
- Endothelial corneal disease
These studies place the sponsor in the field of ophthalmology, particularly around therapies for corneal degeneration and visual rehabilitation.
Metabolic liver disease
The sponsor also funds research in noncirrhotic nonalcoholic steatohepatitis (NASH) with liver fibrosis, reflecting a therapeutic interest in chronic metabolic liver injury and fibrotic progression. The clinical focus is on disease states where inflammation and tissue remodeling contribute to long-term hepatic impairment.
- Noncirrhotic NASH
- Liver fibrosis
- Metabolic liver disease
- Hepatic fibrosis
Its liver-disease portfolio highlights involvement in hepatology and fibrosis-related therapeutic development.
Combination therapy development
In NASH research, Kowa Research Institute Inc. is engaged in studies of combination therapy aimed at addressing fibrotic liver disease through multiple therapeutic mechanisms. This area links metabolic regulation with antifibrotic treatment interests in patients with noncirrhotic liver involvement.
- Combination therapy
- Antifibrotic treatment
- Metabolic regulation
- Chronic liver inflammation
The sponsor’s research activity spans both ocular and hepatic therapeutic domains, with active trial involvement across multiple collaborating sites.
